Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

193.83
+5.422.88%
Pre-market: 193.35-0.4800-0.25%07:39 EST
Volume:7.47M
Turnover:1.44B
Market Cap:466.99B
PE:18.73
High:193.92
Open:189.39
Low:189.05
Close:188.41
52wk High:194.48
52wk Low:140.68
Shares:2.41B
Float Shares:2.40B
Volume Ratio:1.19
T/O Rate:0.31%
Dividend:5.08
Dividend Rate:2.62%
EPS(TTM):10.35
EPS(LYR):5.84
ROE:33.62%
ROA:8.26%
PB:5.89
PE(LYR):33.17

Loading ...

Johnson & Johnson's Zhou Mintao: No Longer Innovating Alone, Fully Integrating into China's Innovation Ecosystem

Deep News
·
Yesterday

"Growing Through Trust" - JNJ International Co Reinforces Global Supply Chain with Hyundai and Kia Genuine Parts

prnewswire
·
Yesterday

New York Closing Stocks

Dow Jones
·
Yesterday

Celldex Therapeutics Appoints Teri Lawver as Chief Commercial Officer

Reuters
·
Nov 10

Johnson & Johnson’s Valuation: Assessing Two New FDA Approvals for DARZALEX FASPRO and CAPLYTA

Simply Wall St.
·
Nov 09

BUZZ-Halozyme Therapeutics down after $1.3 bln convertible bonds sale

Reuters
·
Nov 08

Halozyme: JNJ gets FDA approval for new indication of DARZALEX Faspro

TIPRANKS
·
Nov 07

FDA Approves Johnson & Johnson's DARZALEX FASPRO for High-Risk Smoldering Multiple Myeloma

Reuters
·
Nov 07

Darzalex Faspro® Is the First and Only Treatment Approved by the U.S. FDA for Patients With High-Risk Smoldering Multiple Myeloma

THOMSON REUTERS
·
Nov 07

New York Closing Stocks

Dow Jones
·
Nov 07

Zymeworks Inc. reports third quarter 2025 financial results with $1 million in royalties and $299.4 million in cash resources

Reuters
·
Nov 07

FDA : Approves Daratumumab and Hyaluronidase-Fihj for High-Risk Smoldering Multiple Myeloma

THOMSON REUTERS
·
Nov 07

BUZZ-Alvotech rises as UK clears new arthritis drug

Reuters
·
Nov 06

Texas Attorney General Paxton Asks Judge to Block Kenvue From Paying a Nearly $400 Million Shareholder Dividend Amid Tylenol Lawsuit, Court Filing Shows

THOMSON REUTERS
·
Nov 06

Texas seeks to block Kenvue dividend amid Tylenol lawsuit

Reuters
·
Nov 06

FDA Approves Johnson & Johnson’s CAPLYTA as Adjunctive Therapy for Major Depressive Disorder

Reuters
·
Nov 06

J&J: Caplyta Does Not Need Dose Titration, Allowing Patients to Start Treatment at Effective Dose of 42 Mg

THOMSON REUTERS
·
Nov 06

J&J: FDA Approved Caplyta as an Adjunctive Therapy With Antidepressants for Treatment of Major Depressive Disorder in Adults

THOMSON REUTERS
·
Nov 06

BRIEF-Pharma Mar Receives $10 Mln Milestone Payment From Janssen Products LP

Reuters
·
Nov 06

Pharma Mar - Receives $10 Mln Payment From Janssen for Yondelis Milestone

THOMSON REUTERS
·
Nov 06